From steatosis to cirrhosis: the role of obesity in the progression of liver disease
Open Access
- 14 October 2025
- journal article
- review article
- Published by Springer Nature in Journal of Diabetes & Metabolic Disorders
- Vol. 24 (2) , 1-10
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), the most common subtype of steatotic liver disease (SLD), affects approximately 38% of the global adult population and is strongly linked to obesity, insulin resistance, and type 2 diabetes mellitus (T2DM). Projections estimate its prevalence may exceed 55% by 2040. Obesity plays a central role in the progression from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma. Excess adiposity contributes to hepatic fat accumulation, systemic inflammation, insulin resistance, and activation of hepatic stellate cells. key mechanisms in liver injury and fibrogenesis. Diagnosis traditionally relied on liver biopsy, but noninvasive techniques, along with serum-based indices, are now commonly used. MASLD is associated with an increased risk of cardiovascular disease, chronic kidney disease, and endocrine disorders, particularly in obese individuals. Management is centered on weight reduction, which can reverse steatosis, resolve MASH, and regress fibrosis depending on the degree of weight loss. Recent therapeutic advances include the approval of resmetirom, a thyroid hormone receptor-β agonist, and promising results from glucagon-like peptide 1 (GLP-1) receptor agonists. Bariatric surgery offers significant benefits in selected patients, improving liver histology and associated metabolic parameters. Despite these developments, no universally accepted pharmacotherapy exists for MASLD. Future directions include expanding access to diagnostic tools, validating novel biomarkers, and implementing public health strategies targeting obesity to prevent progression to end-stage liver disease.Keywords
This publication has 48 references indexed in Scilit:
- Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysisJournal of Hepatology, 2021
- Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled TrialsSeminars in Liver Disease, 2021
- Diagnostic Accuracy of FibroScan and Factors Affecting MeasurementsDiagnostics, 2020
- Obesity, Nonalcoholic Fatty Liver Disease and Adipocytokines Network in Promotion of CancerInternational Journal of Biological Sciences, 2019
- Alcohol drinking patterns and liver cirrhosis risk: analysis of the prospective UK Million Women StudyThe Lancet Public Health, 2019
- Obesity is Independently Associated With Increased Risk of Hepatocellular Cancer–related MortalityAmerican Journal of Clinical Oncology, 2018
- Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysisJournal of Hepatology, 2016
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015
- Feeding the critically ill obese patient: a systematic review protocolJBI Evidence Synthesis, 2015
- Non-Alcoholic Fatty Liver Disease Is Associated with an Increased Incidence of Atrial Fibrillation in Patients with Type 2 DiabetesPLOS ONE, 2013